摘要Advanced non-small cell lung cancer(NSCLC)negative for driver genes is a medical oncology treatment challenge.The increasingly widespread application of immunotherapy,especially programmed death-1(PD-1)/programmed death-ligand 1 inhibitors,has changed the treatment pattern of patients with advanced NSCLC.In clinical practice,many patients with immune checkpoint inhibitor(ICI)discontinue treatment for a variety of reasons,and it is known as"immunotherapy rechallenge"to try ICI treatment again following discontinuation.We report an 82-year-old patient with advanced lung adenocarcinoma who was cured after 16 cycles(7.5 months)of PD-1 monoclonal antibody(mab)followed by 4 cycles of bevacizumab and PD-1 mab.Relapse occurred 21 months after treatment had been discontinued.After 10 cycles of immunotherapy,a partial response was achieved,with a 54-month survival and ongoing treatment.This study examines the diagnosis and treatment process,as well as provides a literature review of immunotherapy rechallenge.